Table 2 Baseline characteristics derived from longitudinal study populations
Characteristic | Studies reporting characteristic, N (%) | Category | n (%) or range |
|---|---|---|---|
Study type | 42 (100%) | Prospective Retrospective Predictive model Registry | 27 (64.3%) 10 (23.8%) 3 (7.1%) 2 (4.8%) |
Age (years) | 42 (100%) | – | 29–100 |
Race/ethnicitya | 30 (71.4%) | Caucasian Black Asian Other | 13 (43.3%) 10 (33.3%) 11 (36.7%) 11 (36.7%) |
CKD stage determination | 42 (100%) | CKD stage reported CKD stage inferred CKD undetermined | 2 (4.8%) 36 (85.7%) 4 (9.5%) |
BMI (kg/m2) | 40 (95.2%) | – | 16.5–44.9 |
Diabetes duration (years) | 35 (83.3%) | – | 1–40 |
HbA1c (%) | 39 (92.9%) | – | 5.4–11.9% |
Systolic BP (mm Hg) | 41 (97.6%) | – | 100–182 |
Diastolic BP (mm Hg) | 37 (88.1%) | – | 53–130 |
eGFR (ml/min/1.73m2) | 38 (90.5%) | – | 10–228 |
eGFR assessment methodb | 37 (88.1%) | MDRD CKD-EPI JSN Cockcroft-Gault 51 Cr-EDTA Iohexal clearance Iothalamide clearance | 16 (43.2%) 10 (27.0%) 6 (16.2%) 3 (8.1%) 2 (5.4%) 1 (2.7%) 1 (2.7%) |
ACR (mg/gCR) | 22 (52.4%) | – | 0.5–8603 |
sUA (mg/dL) | 3 (7.1%) | – | 4.9–7.4 |